To address the opioid crisis in rural U.S. regions, the National Institute on Drug Abuse (NIDA), in partnership with several other federal agencies, have issued nine grants to help communities develop comprehensive approaches to prevent and treat consequences of opioid injection, including substance use disorder, overdose, HIV, hepatitis B and C virus infections, as well as sexually transmitted diseases. Once developed, these projects will work with state and local communities to develop best practice responses that can be implemented by public health systems in the nation’s rural regions.
The grants are co-funded by the Appalachian Regional Commission (ARC), the Centers for Disease Control and Prevention (CDC) and the Substance Abuse and Mental Health Services Administration (SAMHSA).
Eight awards were issued in response to the following funding opportunity: HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control.
- April Young, Ph.D. (University of Kentucky) and Hannah Cooper, Sc.D. (Emory University). Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE).
- Judith Feinberg, M.D. and Gordon Smith, M.D. (West Virginia University). Rural West Virginia Responds to Opioid Injection Epidemics: From Data to Action.
- Mai Tuyet Pho, M.D. (University of Chicago) and Wiley Jenkins, Ph.D. (Southern Illinois University School of Medicine). Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC).
- Peter Friedmann, M.D. (Baystate Medical Center) and Richard Rawson, Ph.D. (University of Vermont) Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE).
- Ryan Westergaard, M.D., Ph.D. (University of Wisconsin) and David Seal, Ph.D. (Tulane University). Community-based, client-centered prevention homes to address the rural opioid epidemic.
- Todd Korthuis, M.D. (Oregon Health & Science University). Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study.
- William Miller, M.D. (Ohio State University) and Vivian Go, Sc.D. (University of North Carolina-Chapel Hill). Implementing a Community-Based Response to the Opioid Epidemic in Rural Ohio.
- William Zule, DrPH (Research Triangle Institute). Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern Appalachia.
One award was issued in response to the following funding opportunity: Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States.
- Todd M. Allen, Ph.D. (Massachusetts General Hospital). Next-Generation Sequencing Center for GHOSTing Hepatitis C Virus: Transforming Community Based Molecular Surveillance and Outbreak Investigation.
CDC Press Office: CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
News Media Line – 404-639-8895
NIDA Press Office
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.drugabuse.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®